Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
integrin antagonists	5174	1025967-78-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: lifitegrast SAR 1118-023 SAR 1118 SAR-1118 xiidra	a lymphocyte function-associated antigen-1 ( LFA-1) antagonist, blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1), LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues Molecular weight: 615.48 Formula: C29H24Cl2N2O7S CLOGP: 2.28 LIPINSKI: 1 HAC: 9 HDO: 2 TPSA: 133.99 ALOGS: -5.03 ROTB: 7 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

lifitegrast
SAR 1118-023
SAR 1118
SAR-1118
xiidra

a lymphocyte function-associated antigen-1 ( LFA-1) antagonist, blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1), LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues

Molecular weight: 615.48
Formula: C29H24Cl2N2O7S
CLOGP: 2.28
LIPINSKI: 1
HAC: 9
HDO: 2
TPSA: 133.99
ALOGS: -5.03
ROTB: 7

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value
kinase-safety-class	ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PRKDC,TEK,TGFBR1	22
kinase-selectivity-class	AXL,BRAF,EIF2AK3,GRK2,MAP2K6,PDK1,TEK	7
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
July 11, 2016	FDA	SHIRE DEV LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Instillation site pain	2960.05	28.79	401	8752	529	90618765
Instillation site reaction	2313.71	28.79	300	8853	197	90619097
Eye irritation	1877.70	28.79	474	8679	33504	90585790
Vision blurred	1434.25	28.79	502	8651	109791	90509503
Dysgeusia	815.91	28.79	274	8879	52286	90567008
Eye pain	621.20	28.79	214	8939	43954	90575340
Instillation site pruritus	567.28	28.79	71	9082	17	90619277
Instillation site irritation	566.22	28.79	79	9074	144	90619150
Instillation site erythema	523.53	28.79	67	9086	32	90619262
Instillation site lacrimation	440.07	28.79	54	9099	3	90619291
Ocular hyperaemia	399.36	28.79	144	9009	33654	90585640
Dry eye	333.85	28.79	147	9006	57784	90561510
Lacrimation increased	318.47	28.79	115	9038	26947	90592347
Eye discharge	281.69	28.79	79	9074	8179	90611115
Instillation site discharge	265.17	28.79	33	9120	6	90619288
Instillation site swelling	218.61	28.79	27	9126	3	90619291
Product container issue	205.40	28.79	47	9106	2134	90617160
Eye pruritus	197.78	28.79	83	9070	28944	90590350
Ocular discomfort	190.47	28.79	55	9098	6315	90612979
Instillation site discomfort	169.43	28.79	21	9132	3	90619291
Blood folate decreased	168.11	28.79	38	9115	1632	90617662
Product quality issue	136.09	28.79	90	9063	79235	90540059
Product use complaint	135.16	28.79	37	9116	3496	90615798
Visual impairment	127.32	28.79	106	9047	132259	90487035
Eye disorder	106.40	28.79	53	9100	27337	90591957
Foreign body sensation in eyes	105.38	28.79	30	9123	3270	90616024
Instillation site dryness	103.13	28.79	13	9140	4	90619290
Eye swelling	102.88	28.79	53	9100	29333	90589961
Eyelid margin crusting	98.70	28.79	25	9128	1747	90617547
Instillation site burn	82.01	28.79	10	9143	0	90619294
Product packaging quantity issue	81.37	28.79	21	9132	1581	90617713
Instillation site foreign body sensation	79.39	28.79	10	9143	3	90619291
Instillation site inflammation	76.87	28.79	11	9142	26	90619268
Drug ineffective	69.52	28.79	299	8854	1383999	89235295
Product dose omission issue	68.76	28.79	113	9040	291574	90327720
Inappropriate schedule of product administration	65.22	28.79	78	9075	149855	90469439
Superficial injury of eye	61.92	28.79	13	9140	393	90618901
Swelling of eyelid	59.70	28.79	22	9131	5432	90613862
Product taste abnormal	59.36	28.79	18	9135	2442	90616852
Instillation site hypersensitivity	57.41	28.79	7	9146	0	90619294
Madarosis	52.48	28.79	18	9135	3611	90615683
Burning sensation	51.16	28.79	46	9107	63406	90555888
Instillation site paraesthesia	49.21	28.79	6	9147	0	90619294
Photophobia	48.67	28.79	29	9124	21240	90598054
Asthenopia	44.27	28.79	15	9138	2899	90616395
Erythema of eyelid	42.52	28.79	15	9138	3268	90616026
Abnormal sensation in eye	37.40	28.79	12	9141	1959	90617335
Joint swelling	36.78	28.79	4	9149	503296	90115998
Eyelid irritation	35.98	28.79	10	9143	998	90618296
Arthritis	33.03	28.79	60	9093	167255	90452039
Instillation site haemorrhage	32.80	28.79	4	9149	0	90619294
Vital dye staining cornea present	32.80	28.79	4	9149	0	90619294
Product storage error	32.34	28.79	22	9131	20219	90599075
Product delivery mechanism issue	32.33	28.79	8	9145	508	90618786
Product label issue	31.73	28.79	9	9144	967	90618327
Product packaging issue	31.17	28.79	10	9143	1631	90617663
Periorbital swelling	30.26	28.79	13	9140	4785	90614509
Taste disorder	30.03	28.79	34	9119	61512	90557782

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Instillation site reaction	611.18	78.36	67	1301	19	42619948
Vision blurred	548.40	78.36	154	1214	53545	42566422
Instillation site pain	510.62	78.36	58	1310	44	42619923
Eye irritation	454.50	78.36	98	1270	11220	42608747
Lacrimation increased	142.81	78.36	39	1329	11719	42608248
Instillation site lacrimation	130.93	78.36	14	1354	0	42619967
Eye pain	124.25	78.36	38	1330	16992	42602975
Instillation site erythema	99.45	78.36	11	1357	4	42619963
Ocular hyperaemia	88.86	78.36	29	1339	15934	42604033
Product quality issue	85.62	78.36	29	1339	17853	42602114

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Instillation site pain	2329.27	32.11	292	5322	454	110583231
Instillation site reaction	1834.43	32.11	218	5396	139	110583546
Vision blurred	842.33	32.11	295	5319	128727	110454958
Eye irritation	631.25	32.11	173	5441	33279	110550406
Instillation site erythema	414.24	32.11	49	5565	27	110583658
Dysgeusia	398.16	32.11	145	5469	69840	110513845
Instillation site irritation	382.58	32.11	50	5564	123	110583562
Instillation site pruritus	362.14	32.11	42	5572	13	110583672
Instillation site lacrimation	305.67	32.11	35	5579	6	110583679
Eye pain	255.89	32.11	96	5518	50003	110533682
Ocular hyperaemia	225.31	32.11	82	5532	39204	110544481
Instillation site swelling	183.03	32.11	21	5593	4	110583681
Blood folate decreased	181.51	32.11	38	5576	2297	110581388
Lacrimation increased	164.09	32.11	61	5553	30889	110552796
Instillation site discomfort	160.02	32.11	18	5596	0	110583685
Instillation site discharge	156.41	32.11	18	5596	4	110583681
Eye discharge	154.21	32.11	43	5571	8711	110574974
Product quality issue	127.40	32.11	67	5547	77232	110506453
Product container issue	107.28	32.11	23	5591	1557	110582128
Eye pruritus	92.19	32.11	41	5573	32734	110550951
Dry eye	85.23	32.11	46	5568	55747	110527938
Instillation site burn	80.00	32.11	9	5605	0	110583685
Product dose omission issue	78.69	32.11	89	5525	321693	110261992
Visual impairment	66.81	32.11	55	5559	134373	110449312
Instillation site foreign body sensation	62.22	32.11	7	5607	0	110583685
Foreign body sensation in eyes	61.56	32.11	17	5597	3317	110580368
Eye swelling	61.17	32.11	31	5583	33017	110550668
Instillation site inflammation	59.54	32.11	8	5606	26	110583659
Eyelid margin crusting	54.98	32.11	14	5600	2002	110581683
Instillation site dryness	50.90	32.11	6	5608	3	110583682
Ocular discomfort	49.55	32.11	18	5596	8515	110575170
Drug ineffective	47.14	32.11	176	5438	1520364	109063321
Product use complaint	46.18	32.11	14	5600	3789	110579896
Instillation site paraesthesia	44.44	32.11	5	5609	0	110583685
Abnormal sensation in eye	44.32	32.11	12	5602	2174	110581511
Arthritis	43.70	32.11	48	5566	167538	110416147
Eye disorder	41.81	32.11	23	5591	28883	110554802
Photophobia	41.44	32.11	22	5592	25749	110557936
Inappropriate schedule of product administration	40.88	32.11	51	5563	203586	110380099
Ulcerative keratitis	39.05	32.11	13	5601	4753	110578932
Product packaging quantity issue	37.06	32.11	10	5604	1789	110581896
Instillation site hypersensitivity	35.56	32.11	4	5610	0	110583685

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	S01XA25	SENSORY ORGANS OPHTHALMOLOGICALS OTHER OPHTHALMOLOGICALS Other ophthalmologicals
MeSH PA	D009883	Ophthalmic Solutions
MeSH PA	D019999	Pharmaceutical Solutions
FDA MoA	N0000192700	Lymphocyte Function-Associated Antigen-1 Antagonists
FDA EPC	N0000192701	Lymphocyte Function-Associated Antigen-1 Antagonist
CHEBI has role	CHEBI:35472	anti-inflammatory drug
CHEBI has role	CHEBI:66981	ophthalmology drug
CHEBI has role	CHEBI:133024	lymphocyte function-associated antigen-1 antagonist

Related Drugs by ATC class:

S01XA Other ophthalmologicals 24 drugs

acetylcysteine alteplase alum ascorbic acid avacincaptad pegol cenegermin ciclosporin dexpanthenol diquafosol ethylmorphine guaiazulen heparin show all 24 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Tear film insufficiency	indication	46152009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.42	acidic
pKa2	12.3	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
5%	XIIDRA	BAUSCH AND LOMB INC	N208073	July 11, 2016	RX	SOLUTION/DROPS	OPHTHALMIC	8592450	May 17, 2026	TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5%	XIIDRA	BAUSCH AND LOMB INC	N208073	July 11, 2016	RX	SOLUTION/DROPS	OPHTHALMIC	8367701	April 15, 2029	TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5%	XIIDRA	BAUSCH AND LOMB INC	N208073	July 11, 2016	RX	SOLUTION/DROPS	OPHTHALMIC	9447077	April 15, 2029	TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5%	XIIDRA	BAUSCH AND LOMB INC	N208073	July 11, 2016	RX	SOLUTION/DROPS	OPHTHALMIC	8168655	May 9, 2029	TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Integrin alpha-L/beta-2	Adhesion	P20701 P05107	ITAL_HUMAN ITB2_HUMAN	ANTAGONIST	IC50	8.05		SCIENTIFIC LITERATURE	DRUG LABEL
Intercellular adhesion molecule 1	Antibody	P05362	ICAM1_HUMAN		IC50	8.53		CHEMBL

External reference:

ID	Source
038E5L962W	UNII
D10374	KEGG_DRUG
4035938	VANDF
C3713860	UMLSCUI
CHEBI:133023	CHEBI
CHEMBL2048028	ChEMBL_ID
11965427	PUBCHEM_CID
DB11611	DRUGBANK_ID
CHEMBL2048409	ChEMBL_ID
9584	INN_ID
C575157	MESH_SUPPLEMENTAL_RECORD_UI
7533	IUPHAR_LIGAND_ID
720489009	SNOMEDCT_US
763569006	SNOMEDCT_US
243704	MMSL
31873	MMSL
016935	NDDF
1801820	RXNORM
038E5L962W	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Xiidra	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0911	SOLUTION/ DROPS	50 mg	OPHTHALMIC	NDA	24 sections
Xiidra	HUMAN PRESCRIPTION DRUG LABEL	1	24208-911	SOLUTION/ DROPS	50 mg	OPHTHALMIC	NDA	22 sections
Lifitegrast	Human Prescription Drug Label	1	59651-450	FOR SOLUTION	50 mg	OPHTHALMIC	ANDA	22 sections

Ask DrugCentral

lifitegrast 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: